The American Psychiatric Association’s release of the proposed fifth revision of its billing bible, the Diagnostic and Statistical Manual of Mental Disorders (DSM) fuels University of California’s Dr. Irwin Savodnik’s statement, “The very vocabulary of psychiatry is now defined at all levels by the pharmaceutical industry.”
Psychiatry’s Billing Bible: The Diagnostic and Statistical Manual of Mental Disorders (DSM) The American Psychiatric Association’s Diagnostic and Statistical Manual of Mental Disorders (DSM) is…
The DBSA was originally the National Depressive and Manic-Depressive Association (since 2002, called DBSA), one of the major front groups established in 1986 that could…
Three quarters of nurses have seen people with dementia in general wards in hospital prescribed antipsychotic drugs that are known to double the risk of death and triple the risk of a stroke in these patients, research has shown.
With drug giant GlaxoSmithKline (GSK) now stating it will abandon future antidepressant research, one can only wonder if the U.S. Food and Drug Administration noted GSK’s CEO Andrew Witty’s admission that it is “hard to prove that a depression drug is working” because “patient improvement is measured by subjective mood surveys, and not by the clear-cut blood tests and biological measures used in other diseases.”